The American Journal of Managed Care

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of ...
Seeking Alpha

Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data

Intra-Cellular Therapies, Inc. achieved positive results from Study 501, using lumateperone as an adjunctive therapy for the treatment of patients with MDD; Both primary and secondary endpoints ...
Seeking Alpha

Neumora: Koastal-1 Readout For MDD Treatment Is First Study On Deck

Neumora Therapeutics is set to release data from the phase 3 KOASTAL-1 study using Navacaprant for the treatment of patients with MDD by the end of 2024; other data in 2025. Navacaprant showed ...
pharmaphorum

FDA clears first at-home device for depression

Flow Neuroscience has secured FDA approval for its at-home brain stimulation device, the FL-100 wearable device, as a ...
The American Journal of Managed Care

Lumateperone Improves Depression in Patients With Inadequate Antidepressant Response

Adding lumateperone (Caplyta; Johnson & Johnson) to ongoing antidepressant therapy (ADT) significantly improved depression severity in adults with major depressive disorder (MDD) who had not responded ...